Trial highlights promising frontline therapy for blastic plasmacytoid dendritic cell neoplasm
Educatie
University of Texas M. D. Anderson Cancer Center Feb 11 2026 Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center. The findings were published today in the Journal of Clinical Oncology. The study was
din zilele anterioare